(Q38225315)

31 August 2017

title

PARP inhibition and synthetic lethality in ovarian cancer (English)

1 reference

31 August 2017

1 reference

Ramez N Eskander

1

1 reference

31 August 2017

Krishnansu S Tewari

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

2 July 2014

1 reference

Expert Review of Clinical Pharmacology

31 August 2017

published in

1 reference

31 August 2017

volume

7

1 reference

31 August 2017

issue

5

1 reference

31 August 2017

page(s)

613-622

1 reference

31 August 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Improved survival with bevacizumab in advanced cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

The emerging genetic and molecular basis of Fanconi anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Fanconi anemia and DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

The Fanconi anaemia/BRCA pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Biallelic inactivation of BRCA2 in Fanconi anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Cancer susceptibility and the functions of BRCA1 and BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

DNA double-strand breaks: signaling, repair and the cancer connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Brca1 controls homology-directed DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Improved survival in women with BRCA-associated ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Mutation and cancer: statistical study of retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Present status and problems on molecular targeted therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.930662

10.1586/17512433.2014.930662

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference